Supplementary materials - Indirect treatment comparison of idecabtagene vicleucel versus conventional care in triple-class exposed multiple myeloma
datasetposted on 2022-04-29, 08:37 authored by Ali Mojebi, Ninad Shah, Dieter Ayers, Shannon Cope, Sujith Dhanasiri, Faith E. Davies, Parameswaran Hari, Payal Patel, Kristen Hege, Devender Dhanda
Supplemental Table 1. Study design and patient eligibility criteria for KarMMa and MAMMOTH.
Supplemental Table 2. Summary of patient baseline characteristics in CC population from MAMMOTH with the ide-cel population from KarMMa before and after matching to the CC population from MAMMOTH.